Continuous Process Improvement in the Manufacture of Carfilzomib, Part 1: Process Understanding and Improvements in the Commercial Route to Prepare the Epoxyketone Warhead
- 2 April 2020
- journal article
- research article
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 24 (4) , 481-489
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Patent Review of Manufacturing Routes to Oncology Drugs: Carfilzomib, Osimertinib, and VenetoclaxOrganic Process Research & Development, 2016
- Design, synthesis and biological evaluation of novel tripeptidyl epoxyketone derivatives constructed from β-amino acid as proteasome inhibitorsBioorganic & Medicinal Chemistry, 2014
- Reactivity of Hydroxy- and Aquo(hydroxy)-λ3-iodane-Crown Ether ComplexesChemistry – A European Journal, 2014
- From epoxomicin to carfilzomib: chemistry, biology, and medical outcomesNatural Product Reports, 2013
- A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myelomaBlood, 2012
- Practical Process for the Air Oxidation of Cresols: Part A. Mechanistic InvestigationsOrganic Process Research & Development, 2005
- Epoxomicin, a potent and selective proteasome inhibitor, exhibitsin vivoantiinflammatory activityProceedings of the National Academy of Sciences, 1999
- Hydrogen Bonding between Acetone and Silica Gel, as Studied by NMRThe Journal of Physical Chemistry B, 1999
- The Epoxidation of Certain α,β-Unsaturated Ketones with Sodium HypochloriteThe Journal of Organic Chemistry, 1963